TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36881945

Group type: EXPERIMENTAL
Intervention: Overweight group (OG, n=44, 59% female, mean age 51.68 years, EDSS: 4.71)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lean group (LG, n=62, 71% female, mean age 48.37 years, EDSS: 4.60)
Number of subjects: 106
Study: 36882015

Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro study with Artemisia annua
Number of subjects: 0
Study: 36882136

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1414
Study: 36882181

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo tDCS
Number of subjects: 36
Study: 36882246

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme (3-6 weeks)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 154
Study: 36882302

Group type: EXPERIMENTAL
Intervention: Government-regulated rehabilitation guideline
Number of subjects: 303
Study: 36882409

Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, and dexamethasone
Number of subjects: 0
Study: 36882434

Group type: EXPERIMENTAL
Intervention: Baseline BMI in the range 25.0-29.9 kg/m²
Number of subjects: 18209

Group type: EXPERIMENTAL
Intervention: Baseline waist circumference
Number of subjects: 18209
Study: 36882456

Group type: EXPERIMENTAL
Intervention: H3-WT tumours with ACVR1 or EGFR mutations
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: H3-WT tumours
Number of subjects: 5
Study: 36882474

Group type: EXPERIMENTAL
Intervention: Exogenous Beta-hydroxybutyrate (BHB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 36882483

Group type: EXPERIMENTAL
Intervention: Structured postoperative rehabilitation
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard approach after surgery
Number of subjects: 288
Study: 36882562

Group type: EXPERIMENTAL
Intervention: Oral minocycline 100 mg twice daily for 12 months
Number of subjects: 5
Study: 36882705

Group type: EXPERIMENTAL
Intervention: GAITRite® Platinum Plus Classic (26')
Number of subjects: 95

Group type: COMPARATOR
Intervention: GAITRite® CIRFACE (VI)
Number of subjects: 95
Study: 36882736

Group type: EXPERIMENTAL
Intervention: First-line treatment for HR-/HER2- subtype
Number of subjects: 20033

Group type: EXPERIMENTAL
Intervention: First-line treatment for HR+/HER2+ subtype (monotherapy)
Number of subjects: 20033

Group type: EXPERIMENTAL
Intervention: First-line treatment for HR+/HER2+ subtype (combined therapies)
Number of subjects: 20033
Study: 36882759

Group type: EXPERIMENTAL
Intervention: Intervention group (IG); cycling exercise program, 8 sessions within 3 months.
Number of subjects: 127

Group type: COMPARATOR
Intervention: Active control group (aCG); health recommendations.
Number of subjects: 127
Study: 36882775

Group type: EXPERIMENTAL
Intervention: Socazolimab + nab-paclitaxel + cisplatin (TP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo + nab-paclitaxel + cisplatin (TP)
Number of subjects: 64
Study: 36882804

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 90
Study: 36882942

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Apremilast 30 mg twice daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 66

Group type: COMPARATOR
Intervention: Apremilast
Number of subjects: 66
Study: 36883141

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CCR2/5 antagonist)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Icatibant (bradykinin antagonist)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Apremilast (PDE4 inhibitor)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Celecoxib/Famotidine (COX2/histamine blockade)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Dornase alfa (inhaled DNase)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Razuprotafib (Tie2 agonist)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Dexamethasone and remdesivir
Number of subjects: 392
Study: 36883238

Group type: EXPERIMENTAL
Intervention: danavorexton 112 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 36883362

Group type: EXPERIMENTAL
Intervention: Liraglutide (test drug)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference drug
Number of subjects: 28
Study: 36883379

Group type: EXPERIMENTAL
Intervention: Prescription sleep medications (hypnotics)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia (therapist-led and digital)
Number of subjects: 245
Study: 36883417

Group type: EXPERIMENTAL
Intervention: Pain at diagnosis
Number of subjects: 382
Study: 36883420

Group type: EXPERIMENTAL
Intervention: FLOT plus ramucirumab (Arm B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FLOT alone (Arm A)
Number of subjects: 0
Study: 36883573

Group type: EXPERIMENTAL
Intervention: Sputum Xpert and urine lipoarabinomannan (LAM) test
Number of subjects: 525

Group type: COMPARATOR
Intervention: W4SS
Number of subjects: 525

Group type: COMPARATOR
Intervention: Restricting the use of sputum Xpert, urine LAM test, or CXR to participants with a positive W4SS
Number of subjects: 525
Study: 36883681

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36883881

Group type: EXPERIMENTAL
Intervention: Lumateperone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36883885

Group type: EXPERIMENTAL
Intervention: Doxazosin, dosage and duration not specified
Number of subjects: 0
Study: 36884013

Group type: EXPERIMENTAL
Intervention: D2 antagonist amisulpride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D1 agonist
Number of subjects: 0
Study: 36884024

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5-10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vortioxetine 15-20 mg/day
Number of subjects: 0
Study: 36884035

Group type: EXPERIMENTAL
Intervention: Dose-escalated radiotherapy (RT)
Number of subjects: 5437

Group type: COMPARATOR
Intervention: Conventional dose radiotherapy (RT)
Number of subjects: 5437
Study: 36884108

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous remifentanil at an initial dose of 1 μg/kg lean body weight (LBW), adjusted according to pain severity using the Dixon sequential method.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 89
Study: 36884114

Group type: EXPERIMENTAL
Intervention: Standard deviation of CT features among malignant foci within an individual
Number of subjects: 182

Group type: COMPARATOR
Intervention: Surgery, target therapy, and TNM stage
Number of subjects: 182
Study: 36884116

Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Lymphoma prediction model (combining high SUVmax of the hottest lesion, high SUVmax of retroperitoneal lymph nodes, old age, low platelet count, low ESR)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Score < 4 points
Number of subjects: 163
Study: 36884201

Group type: EXPERIMENTAL
Intervention: Virtual reality relaxation (VR) intervention
Number of subjects: 20
Study: 36884234

Group type: EXPERIMENTAL
Intervention: Methotrexate plus prednisone (20 mg/d for 3 months and 15 mg/d for 3 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Methotrexate for 12 months plus prednisone for 6 months
Number of subjects: 89
Study: 36884238

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 1190
Study: 36884247

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (200 mg twice daily)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 250

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 250
Study: 36884286

Group type: EXPERIMENTAL
Intervention: HEMOPHAR training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community pharmacy or hospital pharmacy dispensing
Number of subjects: 0
Study: 36884302

Group type: EXPERIMENTAL
Intervention: Dabrafenib monotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 25
Study: 36884323

Group type: EXPERIMENTAL
Intervention: Nirogacestat (150 mg, oral, twice daily)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 36888613

Group type: EXPERIMENTAL
Intervention: EMAP program (Engaging Men through Accountable Practice)
Number of subjects: 1387
Study: 36888640

Group type: EXPERIMENTAL
Intervention: Ad5-nCoV vaccine
Number of subjects: 496
Study: 36888687

Group type: COMPARATOR
Intervention: YF-17D+placebo (Group 1)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: YF-17D+TAK-003 (Group 3)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: TAK-003 (Group 2)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 900
Study: 36888686

Group type: EXPERIMENTAL
Intervention: School-based nutrition education intervention including parents' meetings, eight nutrition education sessions, and distribution of educational materials. Nutrition education sessions were conducted once a week for two months.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group with no intervention.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Difference-in-difference analysis of the intervention effect.
Number of subjects: 300
Study: 36888820

Group type: EXPERIMENTAL
Intervention: Balanced solution
Number of subjects: 483

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 483
Study: 36888834

Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation and pulmonary aspiration thrombectomy
Number of subjects: 1
Study: 36888928

Group type: EXPERIMENTAL
Intervention: Bioscore
Number of subjects: 317
Study: 36888930

Group type: EXPERIMENTAL
Intervention: Magrolimab + Azacitidine
Number of subjects: 95
Study: 36888933

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Strength Training
Number of subjects: 462

Group type: COMPARATOR
Intervention: Stretching Control
Number of subjects: 462
Study: 36889160

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5-0.75mg/kg over 40 minutes, four doses over two weeks)
Number of subjects: 100
Study: 36889332

Group type: EXPERIMENTAL
Intervention: Electronic letter highlighting potential cardiovascular benefits of vaccination
Number of subjects: 964870

Group type: EXPERIMENTAL
Intervention: Repeated letters at randomisation and at day 14
Number of subjects: 964870

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 964870
Study: 36889333

Group type: EXPERIMENTAL
Intervention: Immediate complete revascularisation
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Staged complete revascularisation
Number of subjects: 1525
Study: 36889439

Group type: EXPERIMENTAL
Intervention: Panniculus elevation device
Number of subjects: 222

Group type: COMPARATOR
Intervention: No device (control group)
Number of subjects: 222
Study: 36889425

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36889516

Group type: EXPERIMENTAL
Intervention: Nintedanib + prednisone taper
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo + prednisone taper
Number of subjects: 34
Study: 36889524

Group type: EXPERIMENTAL
Intervention: Smartphone-based care platform
Number of subjects: 401

Group type: COMPARATOR
Intervention: Traditional in-person physiotherapy (Control)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 401
Study: 36889610

Group type: EXPERIMENTAL
Intervention: MK-0616 6 mg once daily
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: MK-0616 12 mg once daily
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: MK-0616 18 mg once daily
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: MK-0616 30 mg once daily
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 36889645

Group type: EXPERIMENTAL
Intervention: Combined supplementation of vitamin B12 (1.8 μg) and folic acid (150 μg) for 6 months
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 791

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 791
Study: 36889650

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36889672

Group type: EXPERIMENTAL
Intervention: Total Energy Expenditure (TEE) assessment using doubly labeled water (DLW)
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: Total Energy Expenditure (TEE) assessment in weight-stable subset (532 participants)
Number of subjects: 1131
Study: 36889821

Group type: EXPERIMENTAL
Intervention: Bilateral severely hearing impaired participants with CI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bilateral severely hearing impaired participants without CI
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unilateral severely hearing impaired participants in acute setting
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unilateral severely hearing impaired participants in chronic setting
Number of subjects: 200
Study: 36889826

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) treatment for hyperkalaemia, followed for 6 months.
Number of subjects: 1000
Study: 36889827

Group type: EXPERIMENTAL
Intervention: Sleep quality assessment during a 90-minute visit, evaluating determinants such as morbidity, lifestyles, psychological factors, socioeconomic variables, habitability conditions, screen time, relaxation techniques, and melatonin as a biological marker.
Number of subjects: 500
Study: 36889870

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36889914

Group type: EXPERIMENTAL
Intervention: PrEP (HIV pre-exposure prophylaxis)
Number of subjects: 451
Study: 36890020

Group type: EXPERIMENTAL
Intervention: Mocetinostat 70 mg TIW plus durvalumab 1500 mg Q4W
Number of subjects: 83
Study: 36890072

Group type: EXPERIMENTAL
Intervention: Iron supplementation after bariatric surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No iron supplementation after bariatric surgery
Number of subjects: 0
Study: 36890078

Group type: EXPERIMENTAL
Intervention: 3D Telemedicine
Number of subjects: 66
Study: 36890134

Group type: EXPERIMENTAL
Intervention: BOS 2.0 mg b.i.d.
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: BOS any dose
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 36890253

Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (SME) - turn every other day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rapid maxillary expansion (RME) - 2 turns/day
Number of subjects: 24
Study: 36890329

Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (eHealth positive emotion skills intervention)
Number of subjects: 44
Study: 36890354

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 86
Study: 36890393

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg per day for 7 days
Number of subjects: 12
Study: 36890440

Group type: EXPERIMENTAL
Intervention: Patients diagnosed with SCZ < 2 years
Number of subjects: 271

Group type: COMPARATOR
Intervention: Psychiatric healthy controls
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Patients diagnosed with SCZ ≥ 10 years
Number of subjects: 271
Study: 36890461

Group type: EXPERIMENTAL
Intervention: Family Wellness Program (CHW-led intervention with in-person educational workshops)
Number of subjects: 128
Study: 36890478

Group type: EXPERIMENTAL
Intervention: Community-based support programme for breastfeeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process evaluation of the intervention implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Realist evaluation of the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health economic evaluation of the intervention
Number of subjects: 0
Study: 36890485

Group type: EXPERIMENTAL
Intervention: Ultrasonography to establish accurate gestational age
Number of subjects: 1291
Study: 36890512

Group type: EXPERIMENTAL
Intervention: CMyLife platform (intervention group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Questionnaire group (control)
Number of subjects: 108
Study: 36890526

Group type: EXPERIMENTAL
Intervention: Offering choice of pulmonary rehabilitation location (centre or home)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard practice without choice of location)
Number of subjects: 0
Study: 36890529

Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus tenoxicam injection (TX group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Arthrocentesis alone (control group)
Number of subjects: 30
Study: 36890535

Group type: EXPERIMENTAL
Intervention: Nurse-administered injections
Number of subjects: 318

Group type: COMPARATOR
Intervention: Physician-administered injections
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Task-shifting (nurse-administered)
Number of subjects: 318
Study: 36890548

Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-task gait rehabilitation (DT GR)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Single-task gait rehabilitation (ST GR)
Number of subjects: 300
Study: 36890560

Group type: EXPERIMENTAL
Intervention: FOREST-A Internet-based stress recovery intervention (4-week psychosocial intervention with six modules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study: 36890587

Group type: EXPERIMENTAL
Intervention: Replicating Effective Practices (REP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-Based Quality Improvement (EBQI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VA performance metrics for telehealth care delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stages of Implementation Completion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation experiences among multilevel stakeholders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost and return on investment
Number of subjects: 0
Study: 36890595

Group type: EXPERIMENTAL
Intervention: Free sugar intake from snacks (FS)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Free sugar intake from beverages (FS)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Total free sugar intake from snacks and beverages
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Top snack sources of FS
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Top beverage sources of FS
Number of subjects: 267
Study: 36890601

Group type: EXPERIMENTAL
Intervention: High-intensity exercise program guided by HRV
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moderate to high-intensity preplanned exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 90
Study: 36890644

Group type: EXPERIMENTAL
Intervention: Intradialytic magnetic resonance imaging and spectroscopy during hemodialysis
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy during hemodialysis
Number of subjects: 17
Study: 36890688

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Turner syndrome participants
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: snp11547635 heterozygosity
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: TGFβ and TIMP's
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: TGFβ1 and TIMP4
Number of subjects: 87
Study: 36890729

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (n=72)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Monthly erythrocyte transfusions (n=40)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No disease-modifying therapy (n=58)
Number of subjects: 204
Study: 36890738

Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment (IPT)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Direct pulp capping (DPC)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Partial pulpotomy (PP)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Pulpotomy
Number of subjects: 216
Study: 36890753

Group type: EXPERIMENTAL
Intervention: Each additional lifetime partner
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Each additional number of substances used in adolescents' lifetime
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Each one standard deviation increase in depression severity (in boys)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Each 1-unit increase in positive prospections of pregnancy
Number of subjects: 445
Study: 36891030

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block (TMQLB) with 0.4 ml/kg of 0.5% ropivacaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Thoracic paravertebral block (PVB) with 0.4 ml/kg of 0.5% ropivacaine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block (TMQLB)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Thoracic paravertebral block (PVB)
Number of subjects: 68
Study: 36891077

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 3 years
Number of subjects: 1828

Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 3 years
Number of subjects: 1828
Study: 36891618

Group type: EXPERIMENTAL
Intervention: Gaining-accurate-prognostic-awareness
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Maintaining-accurate-prognostic-awareness
Number of subjects: 334

Group type: COMPARATOR
Intervention: Maintaining-inaccurate/unknown-prognostic-awareness
Number of subjects: 334
Study: 36891649

Group type: EXPERIMENTAL
Intervention: MI-CBT (Motivational Interviewing and Cognitive-Behavioral Therapy)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Mindfulness control condition
Number of subjects: 79